This content is machine translated MASLD/MASH Drug therapy options on the rise: spectacular evidence Over the last few decades, the incidence of steatotic liver disease has risen in parallel with the increase in obesity, diabetes and other metabolic diseases. It is recommended to screen...…
View Post 4 min This content is machine translated Psoriasis and metabolic comorbidities: new study data GLP-1RAs showed a valuable dual benefit GLP-1RAs, including semaglutide and liraglutide, are frequently used today for the treatment of type 2 diabetes and obesity. A recent study investigated whether and how overweight and/or diabetic psoriasis patients...…
View Post 3 min This content is machine translated Development of a quintuple agonist New strategy in the fight against obesity and T2D The treatment of obesity and type 2 diabetes is increasingly shifting to newer incretin drugs, including GLP1 receptor agonists (single agonists such as semaglutide) and GIP- and GLP1-RA (dual agonists...…
View Post 6 min This content is machine translated Obesity in the family practice Aim for realistic goals and avoid apportioning blame Morbid obesity is a significant health risk factor and its prevalence has increased in many industrialized countries in recent years. The principles of weight reduction have hardly changed over the...…
View Post 4 min This content is machine translated Obesity Extent of weight reduction is prognostically relevant According to the World Health Organization (WHO), obesity is one of the greatest health risks. With increasing severity, the risk of various concomitant and secondary diseases increases. Obesity-related multimorbidity is...…
View Post 7 min This content is machine translated Steatotic liver disease GLP-1RA in MASH – what’s new? Metabolic dysfunction-associated steatohepatitis (MASH) corresponds tothe liver disease formerly known as non-alcoholic fatty liver inflammation (NASH). The most common causes of MASH are obesity and diabetes. There are still no...…
View Post 4 min This content is machine translated Study report: Obesity New findings on the effects of incretin analogs A study by Aronne et al. investigated the effects of the dual GLP1/GIP receptor agonist (RA) tirzepatide in obese patients when it is administered over a longer period of therapy...…
View Post 5 min This content is machine translated Metabolic Dysfunction-Associated Steatotic Liver Disease Cardiology and hepatology in one boat Metabolic dysfunction has far-reaching negative effects on the body, which can manifest as cardiovascular and liver disease. Traditionally, these conditions have been treated in an organ-centered manner, resulting in isolated…
View Post 6 min This content is machine translated Obesity therapy Why lifestyle modification alone is not effective According to current understanding, obesity is considered a multifactorial chronic disease. The overriding goals of treatment are to improve the general state of health and weight-associated diseases or risk factors.…
View Post 5 min This content is machine translated Obesity The pounds tumble under incretin-based therapies Antiadiposita can effectively support the success of lifestyle interventions and thus close a treatment gap. In Switzerland, the GLP-1 RAs liraglutide and semaglutide are currently the most effective in the…
View Post 5 min This content is machine translated Obesity GLP-1-based drugs close the treatment gap The WHO has declared obesity to be a global health problem and weight reduction is an important measure in the prevention and treatment of metabolic diseases such as type 2…
